Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 22 Aug - Newspaper Advertisement-Information regarding 79th Annual General meeting and E-voting
Source: Bse
Indoco Remedies Limited (INDOCO)
Small CapPharma stocks · Small cap · NSE
Indoco Remedies Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result28 Jul, 05:29 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
69BullishMACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 49
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
INDOCOD candles · FIT view+14.6%Latest close ₹236.50 on 2026-10-19
Bar
-3.5%
RSI
46
MACD hist
-1.24
52W pos
58%
2026-10-19O ₹245.00H ₹245.00L ₹235.10C ₹236.50Vol 87,615 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
INDOCONifty PharmaNifty 500
- INDOCO
- -3.3%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +2.3 pp
Chart stats
19 Oct 2026- From 52W high
- -25.5%
- 52W range position
- 48%
- ATR (14)
- 5.8%
- Volume vs 20D
- 0.07x
- Avg traded value
- ₹33.8 Cr
- 20D price channel
- ₹220.7 - ₹284.8
₹317.4
₹162.2 - ₹317.4
₹13.6
Latest completed session
20-session average
47.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED18
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad25
Revenue +6.4% · PAT NDF YoY
Technical
Bullish69
Price trend and sector-relative-strength timing.
Valuation
Legacy model-10580.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence56
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 25/100Rev +6% YoY · margin expansion
Filed 28 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹468 Cr | +6.4% | -1.7% |
| EBITDA | ₹41 Cr | +127.8% | -18.0% |
| Operating margin | 9.0% | +500 bps | -100 bps |
| PAT | ₹65 Cr | NDF | NDF |
| PAT margin | 13.9% | +2207 bps | +1893 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 2.42
- EV/EBITDA
- 11.38
- Market Cap
- 2278.00Cr
Profitability
- ROE
- -9.36%
- ROCE
- 0.96%
- ROA
- 0.12%
- Dividend Y
- 0.08%
Growth (CAGR)
- Revenue 5Y
- 8.00%
- EPS 5Y
- -11.00%
- Revenue 3Y
- 3.00%
- EPS 3Y
- -9.00%
Balance Sheet
- Debt/Equity
- 1.16
- Interest Coverage
- 1.33×
- Altman Z
- 2.39
- Book Value
- 102.00
Cash Flow
- FCF Yield
- 3.95%
- FCF Positive Y
- 7/5
- OCF
- 192.00 Cr
- EPS TTM
- 0.61
Shareholding
- Promoter Hold
- 58.86%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 55%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 468-1.7% vs prev
Net Profit
₹ CrLatest: 65.0+370.8% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term uptrend intact. RSI 46.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 roughly flat — short-term momentum stalled.
- RSI(14) at 46 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 19% off 52W high · 46% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
57
RS percentile
Stage 2 UptrendNew S2
1M return
-5.0%
3M return
-3.3%
6M return
+10.4%
1Y return
-13.4%
RS 1D
-3
RS 20D
0
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 4.5% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +2.9%.
50-DMA
price below
200-DMA
price above
S2 entered
14 Oct 2026
S2 age
4 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 85.27-2.73%
RS vs Nifty 50085
Valuation & peers
U-Score 18 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 18 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation3/30
Growth4/25
Quality0/20
Balance Sheet4/15
Cash Flow6/10
Piotroski
4/9 (+1)
Penalties
0
Raw sum
18
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
18/100 · legacy band OVERVALUED
Positive drivers
- FCF yield is supportive at 4.0%.
- Cash flow contributes 6/10 to the score.
- Balance sheet contributes 4/15 to the score.
Main drags
- Fair-value margin of safety is negative at -10580.4%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Valuation is weaker at 3/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
2.4
EV/EBITDA
11.4
ROE
-9.4%
ROCE
1.0%
FCF Yield
4.0%
Debt/Equity
1.2
MoS
-10580.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
18
Previous: 18
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-10580.4%
Previous: -10580.4%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
18
18
18
18
18
18
18
18
18
18
18
18
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹37.42
-532.1% MoS
Growth-justified P/E
3.6
Growth-justified Value
₹2.21
-10580.4% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SAKAR
Small
Sakar Healthcare Limited
Healthcare Services
match 166
38
62.1
10.0%
-26%
WATCHLIST
KRSNAA
Small
Krsnaa Diagnostics Limited
Healthcare Services
match 165
30
18.6
10.9%
-277%
OVERVALUED
SYNCOMF
Small
Syncom Formulations (India) Limited
Healthcare Services
match 164
66
25.4
17.6%
+48%
UNDERVALUED
VENUSREM
Small
Venus Remedies Limited
Healthcare Services
match 163
67
20.5
15.6%
+59%
UNDERVALUED
VIMTALABS
Small
Vimta Labs Limited
Healthcare Services
match 163
58
31.6
18.9%
+37%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Indoco Remedies Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
56Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 18th percentile of the scored universe and 13th percentile within Pharma. Main check: financial discipline is weak at 30/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
63 docs text-extracted · 46 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
18th percentile
overall median 67 · Pharma: 13th pctile, median 70 · Small: 20th pctile, median 66
Evidence depth
Financial-only
63 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
39
weak · leverage and solvency
Discipline
30
weak · capital discipline
Results
39
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 58.9%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 3.7%.
- ▸7 years of positive FCF.
Trust risks
- ▸4 latest quarters had PAT decline worse than 25% YoY.
- ▸Debt/equity is 1.16.
- ▸Interest coverage is 1.3x.
- ▸ROCE is low at 1%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Indoco Remedies Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Notice Of 79Th Annual General Meeting And Annual Report For The Financial Year 2025-2026 21 Aug
Source: Bse
Annual report
Notice Of 79Th Annual General Meeting And Annual Report For The Financial Year 2025-2026 21 Aug
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.